DAX22.840 -2,8%Est505.614 -2,1%MSCI World4.343 -0,1%Top 10 Crypto9,4100 -2,0%Nas22.091 -0,3%Bitcoin60.965 -2,0%Euro1,1586 +1,1%Öl107,6 -1,9%Gold4.652 -3,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Vonovia A1ML7J Rheinmetall 703000 Siemens Energy ENER6Y SAP 716460 NVIDIA 918422 Lufthansa 823212 DroneShield A2DMAA Volkswagen (VW) vz. 766403 Deutsche Telekom 555750 Allianz 840400 Infineon 623100 Micron Technology 869020 Shell (ex Royal Dutch Shell) A3C99G Deutsche Bank 514000 Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach EZB-Zinsentscheid: DAX schließt tiefrot -- Wall Street schwach -- Micron-Zahlen: Gewinn vervielfacht -- Equinor, Rivian, Uber, Samsung, Rüstungsaktien, Siemens Energy, Tesla, NVIDIA, BYD im Fokus
Top News
Ausblick: Xpeng legt die Bilanz zum abgelaufenen Quartal vor Ausblick: Xpeng legt die Bilanz zum abgelaufenen Quartal vor
"Macrohard" als Wendepunkt für die Tesla-Aktie? Das steckt hinter dem gemeinsamen Projekt mit xAI "Macrohard" als Wendepunkt für die Tesla-Aktie? Das steckt hinter dem gemeinsamen Projekt mit xAI
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Noch bis 13. April bei der Commerzbank gebührenfrei in Vanguard-ETFs investieren
Wer­bung

Jazz Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
157,00 EUR -0,06 EUR -0,04 %
BMN
181,72 USD +1,27 USD +0,70 %
BTT
finanzen.net zero
Jazz Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.9,69 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JS1K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIE00B4Q5ZN47

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJAZZ

Jazz Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireJazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR NewswireJazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
PR NewswireJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR NewswireJazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR NewswireJazz Pharmaceuticals Completes Acquisition of Chimerix
PR NewswireJazz Pharmaceuticals Completes Acquisition of Chimerix
PR NewswireJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
PR NewswireJazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Aca...
PR NewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
PR NewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
PR NewswireJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireJazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireJazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR NewswireJazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR NewswireJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireJazz Pharmaceuticals Announces CEO Succession Plan
PR NewswireJazz Pharmaceuticals Announces CEO Succession Plan
PR NewswireJazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Societ...
PR NewswireJazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
PR NewswireJazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
PR NewswireJazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
PR NewswireJazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
PR NewswireJazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract...
PR NewswireJazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
PR NewswireJazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
PR NewswireJazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
PR NewswireJazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic H...
PR NewswireJazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
PR NewswireJazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
PR NewswirePharmaMar gibt positive und statistisch signifikante Ergebnisse zum Gesamtüberleben und zum progressionsfreien Überleben für die Kombination aus Zepzelca® (Lurbinectedin) und Atezolizumab in der E...
PR NewswirePharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenan...
PR NewswireJazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance...
PR NewswireJazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

Jazz Pharmaceuticals News

Jazz Pharmaceuticals News: auf dieser Seite finden Sie alle Jazz Pharmaceuticals News und Nachrichten zur Jazz Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Jazz Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Jazz Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.